Catalysis and Inhibition of Gelatinases
Catalysis and Inhibition of Gelatinases
批准号:
7767704
负责人:
D. K SRIVASTAVA
金额:
$24.56万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-03-16 至 2013-02-28
关键词:
Adverse effectsAreaBindingCancer cell lineCancerousCatalysisCell LineCleaved cellCollagen Type IVEffectivenessElectronicsEncapsulatedEnzyme Inhibitor DrugsEnzyme InhibitorsEnzyme KineticsEnzymesExhibitsFatty AcidsFibronectinsGelatinase AGelatinasesHistidineIonsIsoenzymesKnowledgeLeadLigandsLightLipidsLiposomesMalignant Epithelial CellMatrix MetalloproteinasesMediatingMolecular ConformationMolecular ModelsMolecular and Cellular BiologyNMR SpectroscopyNeoplasm MetastasisOrganic ChemistryOutcomePeptidesPharmaceutical PreparationsPhysiologicalPreventionPrevention strategyProceduresRecombinantsResearchRoleSiteSpectrum AnalysisStructureSurfaceSystemTechniquesThermodynamicsTissuesTitrationsTransition ElementsVesicleWound Healinganticancer researchbasecancer therapydesigninhibitor/antagonistmolecular modelingpreventresearch studytargeted deliverytumortumor progression
中文摘要
这项研究的长期目标是研究明胶酶在促进
癌组织中的侵袭和转移,以及通过设计基于
抑制剂作为潜在药物。除了它们在组织重塑、伤口愈合等方面的生理作用外,
明胶酶-A和明胶酶-B与癌症进展和转移密切相关。因此,
作为潜在药物的针对这些酶的选择性抑制剂,以及它们向肿瘤部位的受控递送
在癌症研究领域具有重要意义。在研究过程中,我们将
研究明胶酶-A和-B切割其序列特异性的基本机制
(合成的)三螺旋肽(与脂肪酸缀合以及掺入脂质囊泡中),
合成针对这些酶的基于机制的抑制剂,并标准化程序,
靶向递送至选定的癌细胞系。拟议研究的具体目标包括:
(1)探讨明胶酶-A和-B对序列特异性切割的选择性和效率
三螺旋肽及其脂肪酸缀合物,(2)设计基于结构的明胶酶抑制剂,
A和-B,并确定其效力,(3)制定策略,以提供抑制剂在选定的
癌细胞系,并评估其在预防细胞侵袭中的有效性。这些目标将
通过采用合成有机化学,细胞和分子生物学,
电子光谱学、酶动力学和热力学以及分子模型构建方法。
拟议研究的结果将导致癌症的预防和/或治疗。
英文摘要
The long term objective of the proposed research is to investigate the role of gelatinases in promoting
invasion and metastasis in cancerous tissues, and its prevention by designing the mechanism based
inhibitors as potential drugs. Besides their physiological roles in tissue remodeling, wound healing etc.,
gelatinase-A and -B are intimately involved in cancer progression and metastasis. Hence, the design of
selective inhibitors against these enzymes as potential drugs, and their controlled delivery to the tumor sites
are of significant importance in the area of the cancer research. During the proposed research, we will
investigate the fundamental mechanism by which gelatinase-A and -B cleave their sequence specific
(synthetic) triple-helical peptides (conjugated with fatty acids as well as incorporated in the lipid vesicles),
synthesize the mechanism based inhibitors against these enzymes, and standardize the procedures for
targeted delivery to selected cancer cell lines. The specific aims of the proposed research include the
following: (1) Probe the selectivity and efficiency of gelatinase-A and -B in cleaving the sequence specific
triple helical peptides and their fatty acid conjugates, (2) Design the structure based inhibitors for gelatinase-
A and -B, and ascertain their potencies, (3) Develop strategy for delivering the inhibitors in selected
carcinoma cell lines, and assess their effectiveness in preventing cellular invasions. These objectives will be
accomplished by employing the techniques of synthetic organic chemistry, cellular and molecular biology,
electronic spectroscopy, enzyme kinetics and thermodynamics, and molecular model building approaches.
The outcome of the proposed research will lead to the prevention and/or treatment of cancers.
期刊论文(11)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Recognition of isozymes via lanthanide ion incorporated polymerized liposomes.
通过掺入稀土离子的聚合脂质体识别同工酶。
DOI:
10.1039/b709815d
发表时间:
2007
期刊:
Chemical communications (Cambridge, England)
影响因子:
--
作者:
[Elegbede,AdekunleI, Haldar,ManasK, Manokaran,Sumathra, Mallik,Sanku, Srivastava,DK]
通讯作者:
Srivastava,DK
DOI:
10.1166/jbn.2008.009
发表时间:
2008-12-01
期刊:
Journal of biomedical nanotechnology
影响因子:
2.9
作者:
[Manokaran S, Berg A, Zhang X, Chen W, Srivastava DK]
通讯作者:
Srivastava DK
DOI:
10.1021/mp500108p
发表时间:
2014-07-07
期刊:
Molecular pharmaceutics
影响因子:
4.9
作者:
[Kulkarni PS, Haldar MK, Nahire RR, Katti P, Ambre AH, Muhonen WW, Shabb JB, Padi SK, Singh RK, Borowicz PP, Shrivastava DK, Katti KS, Reindl K, Guo B, Mallik S]
通讯作者:
Mallik S
DOI:
10.1021/bi8019542
发表时间:
2009-02-24
期刊:
BIOCHEMISTRY
影响因子:
2.9
作者:
[Berg, Alexander K., Srivastava, D. K.]
通讯作者:
Srivastava, D. K.
DOI:
10.1021/ja801548g
发表时间:
2008-08-13
期刊:
Journal of the American Chemical Society
影响因子:
15
作者:
[Elegbede AI, Banerjee J, Hanson AJ, Tobwala S, Ganguli B, Wang R, Lu X, Srivastava DK, Mallik S]
通讯作者:
Mallik S
共 7 条
Isozyme Selectivity among Triple Helix Cleaving Metalloproteinases
-
批准号:8688659
-
项目类别:
-
资助金额:$34.71万
-
财政年份:2014
-
负责人:D. K SRIVASTAVA
-
依托单位:
Catalysis and Inhibition of Gelatinases
-
批准号:7208976
-
项目类别:
-
资助金额:$24.12万
-
财政年份:2006
-
负责人:D. K SRIVASTAVA
-
依托单位:
Catalysis and Inhibition of Gelatinases
-
批准号:7033473
-
项目类别:
-
资助金额:$24.54万
-
财政年份:2006
-
负责人:D. K SRIVASTAVA
-
依托单位:
Catalysis and Inhibition of Gelatinases
-
批准号:7354759
-
项目类别:
-
资助金额:$24.56万
-
财政年份:2006
-
负责人:D. K SRIVASTAVA
-
依托单位:
Catalysis and Inhibition of Gelatinases
-
批准号:7570618
-
项目类别:
-
资助金额:$24.56万
-
财政年份:2006
-
负责人:D. K SRIVASTAVA
-
依托单位:
Molecular Basis of Preconditioning
-
批准号:6804329
-
项目类别:
-
资助金额:$21.15万
-
财政年份:2004
-
负责人:D. K SRIVASTAVA
-
依托单位:
A Disease Causing Mutation in Acyl-CoA Dehydogenase
-
批准号:6316139
-
项目类别:
-
资助金额:$10.58万
-
财政年份:2001
-
负责人:D. K SRIVASTAVA
-
依托单位:
SMALL INSTRUMENTATION GRANT
-
批准号:3524857
-
项目类别:
-
资助金额:$0.5万
-
财政年份:1991
-
负责人:D. K SRIVASTAVA
-
依托单位:
ENZYME-ENZYME INTERACTIONS AND KINETICS
-
批准号:3291987
-
项目类别:
-
资助金额:$6.45万
-
财政年份:1989
-
负责人:D. K SRIVASTAVA
-
依托单位:
国内基金
海外基金
层出镰刀菌氮代谢调控因子AreA 介导伏马菌素 FB1 生物合成的作用机理
-
批准号:2021JJ40433
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2021
-
负责人:孙磊
-
依托单位:
寄主诱导梢腐病菌AreA和CYP51基因沉默增强甘蔗抗病性机制解析
-
批准号:32001603
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:段真珍
-
依托单位:
AREA国际经济模型的移植.改进和应用
-
批准号:18870435
-
项目类别:面上项目
-
资助金额:2.0万元
-
批准年份:1988
-
负责人:史树中
-
依托单位: